Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma Corp (ABUS) is the subject of BlackRock, Inc.'s amended beneficial-ownership report. BlackRock reported beneficial ownership of 14,331,732 common shares, or 7.2% of the class, as of September 30, 2026. It reported sole voting power over 14,033,488 shares and sole dispositive power over 14,331,732 shares; shared voting and dispositive power were both zero. BlackRock stated that various persons could receive dividends or sale proceeds tied to the shares, but no one person's interest exceeded 5% of the total outstanding common shares.
Arbutus Biopharma Corp. (ABUS) announced that the FDA removed the clinical hold on the Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, and notified the company that it may engage in additional clinical development in the United States. Arbutus is evaluating next steps.
AB-101 completed a Phase 1a/1b trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects and people with chronic HBV, using single- and multiple-ascending oral doses. The company said the candidate was generally well-tolerated; results showed evidence of high receptor occupancy in seven chronic HBV patients and hepatitis B surface antigen decline in two at the 30 mg dose. AB-101 is designed to inhibit PD-L1, with potential to activate an HBV-specific immune response.
Morgan Stanley reported beneficial ownership of 18,682,708 Arbutus Biopharma Corp (ABUS) common shares, or 12.2% of the class. Morgan Stanley Investment Management Inc. reported beneficial ownership of 17,376,366 shares, or 11.3%.
Morgan Stanley reported shared voting power over 18,663,982 shares and shared dispositive power over 18,668,111 shares. Morgan Stanley Investment Management Inc. reported shared voting and dispositive power over 17,376,366 shares. The disclosure covers securities beneficially owned or deemed owned by certain Morgan Stanley operating units and excludes units whose ownership is disaggregated under the cited SEC release.
Robert A. Beardsley reported disposition transactions in this Form 4 filing. Arbutus Biopharma Corp (ABUS) director Robert A. Beardsley tendered 17,948 common shares to the issuer under its tender offer. The issuer took up and accepted the shares for payment on October 1, 2026, at $5 per share. Beardsley reported direct holdings of 14,328 common shares following the transaction.
Tuan Nguyen reported disposition transactions in this Form 4 filing. Arbutus Biopharma Corp (ABUS) took up and accepted for payment 48,081 common shares tendered by Chief Financial Officer Tuan Nguyen under its tender offer, at $5.00 per share. The company accepted the shares on October 1, 2026. Nguyen reported direct holdings of 111,882 common shares afterward; no Rule 10b5-1 plan is reported.
Roger Sawhney reported disposition transactions in this Form 4 filing. Arbutus Biopharma Corp (ABUS) director Roger Sawhney tendered 17,142 common shares from his direct holdings to the issuer under its tender offer at $5.0000 per share. The issuer took up and accepted the shares for payment on October 1, 2026. Sawhney held 13,683 common shares directly after the transaction.
Arbutus Biopharma Corp's President and CEO, Lindsay Androski, returned 24,655 common shares to the issuer in its tender offer at $5.00 per share on October 1, 2026. The issuer took up and accepted the shares for payment that day. Androski held 47,682 common shares directly following the transaction. No Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp announced it had accepted 46,000,000 Common Shares at US$5.00 per share in its issuer tender offer. The offer sought to purchase for cancellation up to US$230 million of Common Shares at prices between US$5.00 and US$5.75 per share.
Roivant Sciences Ltd. tendered 8,967,383 shares, which were accepted at US$5.00 per share for aggregate consideration of approximately US$44,836,915. After the offer, Roivant reported beneficial ownership of 29,880,079 shares, approximately 19.5% of outstanding shares, and sole voting and dispositive power. Roivant stated that it disclaims beneficial ownership except to the extent of its pecuniary interest.
Arbutus Biopharma Corp. reports that Roivant Sciences Ltd. returned 8,967,383 common shares to the issuer on October 1, 2026, at $5 per share. Roivant directly held 29,880,079 shares afterward. Roivant is a 10% owner and may be deemed a director by deputization; no Rule 10b5-1 plan is reported.
Arbutus Biopharma Corporation’s issuer tender offer sought to purchase common shares for an aggregate purchase price not exceeding US$230 million, at prices from US$5.00 to US$5.75 per share, in cash without interest. The offer expired at 5:00 p.m. New York City time on September 29, 2026. On October 1, 2026, the company issued a press release announcing the final results.